NCT00402532 is a Phase 3 clinical trial of Everolimus in Lung Transplantation, sponsored by Hannover Medical School.

Who is sponsoring NCT00402532?

NCT00402532 is sponsored by Hannover Medical School.

What drugs are being tested in NCT00402532?

Interventions in NCT00402532: Everolimus, Mycophenolatmofetil.

What condition does NCT00402532 study?

NCT00402532 studies Lung Transplantation.

Is NCT00402532 still recruiting?

NCT00402532 is currently completed. Last updated 7 December 2011.

Last reviewed 2011-12-07 · How we verify

NCT00402532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

Completed Phase 3 Last updated 7 December 2011

What this trial tests

Phase 3 trial testing Everolimus in Lung Transplantation in 190 participants. Completed in 1 December 2011.

Timeline

1 March 2005

Primary endpoint
1 November 2011

1 December 2011

Quick facts

Lead sponsor	Hannover Medical School
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	190
Start date	1 March 2005
Primary completion	1 November 2011
Estimated completion	1 December 2011
Sites	1 location across Germany

Drugs / interventions tested

Everolimus (everolimus) — full drug profile →
Mycophenolatmofetil — full drug profile →

Conditions studied

Lung Transplantation — all drugs for Lung Transplantation →

Sponsor

Hannover Medical School

Who can join

Adults 18 to 65, any sex, with Lung Transplantation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence and severity of bronchiolitis obliterans syndrome and mortality and need for change of immunosuppressive medication within 2 years from transplantation
Time frame: 2 years

Sponsor's own description

The purpose of this study is to determine whether Everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation.
Gräger N, Leffler M, Gottlieb J, Fuge J, et al · · 2019 · cited 12× · PMID 30984427 · DOI 10.1155/2019/7089482

Verify or expand the search:

Other trials of Everolimus

Trials testing the same drug.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting

Other recruiting trials for Lung Transplantation

Currently open trials in the same condition.

NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
NCT06853223 — This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction · Phase 2 · recruiting
NCT06868823 — Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation · recruiting
NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
NCT06327945 — Transplanting Lungs From Uncontrolled Donation After Circulatory Death · NA · recruiting

Other Hannover Medical School trials

Trials by the same sponsor.

NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00402532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
Last refreshed: 7 December 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00402532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing